Search results
Results from the WOW.Com Content Network
The dendritic cell-based cancer vaccine is an innovation in therapeutic strategy for cancer patients. Dendritic cells (DCs) are antigen presenting cells for the induction of antigen specific T cell response. [1] DC-based immunotherapy is safe and can promote antitumor immune responses and prolonged survival of cancer patients. [2]
Pain and sensory abnormalities can persist for months or years after treatment completion. Some patients may experience “coasting,” where symptoms intensify after completion of treatment. [3] As such, patients can be cancer-free and still suffer from disabling neuropathy induced by cancer treatment. [3]
They are usually given intravenously, shortly before administration of the chemotherapeutic agent, [3] although some authors have argued that oral administration may be preferred. [4] The concomitant administration of a NK 1 receptor antagonist , such as aprepitant , significantly increases the efficacy of 5-HT 3 antagonists in preventing both ...
Checkpoint inhibitor therapy is a form of cancer immunotherapy. The therapy targets immune checkpoints, key regulators of the immune system that when stimulated can dampen the immune response to an immunologic stimulus. Some cancers can protect themselves from attack by stimulating immune checkpoint targets.
A SERS-based multiplex protein biomarker detection platform in a microfluidic chip can be used to detect several protein biomarkers to predict the type of disease and critical biomarkers and increase the chance of diagnosis between diseases with similar biomarkers (e.g. pancreatic cancer, ovarian cancer, and pancreatitis).
In the cancer disease state, the interaction of PD-L1 on the tumor cells with PD-1 on a T-cell reduces T-cell function signals to prevent the immune system from attacking the tumor cells. [9] Use of an inhibitor that blocks the interaction of PD-L1 with the PD-1 receptor can prevent the cancer from evading the immune system in this way. [9]
Immunoglobulin therapy is the use of a mixture of antibodies (normal human immunoglobulin) to treat several health conditions. [23] [24] These conditions include primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain–Barré syndrome, and certain other infections when a ...
An example of such adjuvant therapy is the additional treatment [1] usually given after surgery where all detectable disease has been removed, but where there remains a statistical risk of relapse due to the presence of undetected disease. If known disease is left behind following surgery, then further treatment is not technically adjuvant.